Extended report: Sirukumab a human anti-interleukin-6 monoclonal antibody: a randomised 2-part (proof-of-concept and dose-finding) phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

摘要

ObjectivesThe safety and efficacy of sirukumab, an anti-interleukin-6 (IL-6) monoclonal antibody, were evaluated in a 2-part, placebo-controlled phase II study of patients with active rheumatoid arthritis (RA) despite methotrexate therapy.